Paratek Pharmaceuticals, Inc.

Symbol: PRTK

NASDAQ

2.23

USD

Market price today

  • -3.0521

    P/E Ratio

  • 0.1791

    PEG Ratio

  • 127.83M

    MRK Cap

  • 0.00%

    DIV Yield

Paratek Pharmaceuticals, Inc. (PRTK) Stock Price & Analysis

Shares Outstanding

0M

Gross Profit Margin

0.85%

Operating Profit Margin

-0.20%

Net Profit Margin

-0.30%

Return on Assets

-0.29%

Return on Equity

0.22%

Return on Capital Employed

0.49%

Company general description and statistics

Sector: Healthcare
Industry: Biotechnology
CEO:Dr. Evan Loh FACC, FAHA, M.D.
Full-time employees:268
City:Boston
Address:75 Park Plaza
IPO:2009-02-03
CIK:0001178711

Paratek Pharmaceuticals, Inc., a commercial-stage biopharmaceutical company, focuses on the development and commercialization of life-saving therapies for life-threatening diseases or other public health threats for civilian, government, and military use. Its lead product candidates include NUZYRA, a once-daily oral and intravenous broad-spectrum antibiotic for the treatment of adult patients with community-acquired bacterial pneumonia and acute bacterial skin and skin structure infections caused by susceptible pathogens; and SEYSARA, a tetracycline designed for the treatment of moderate to severe acne vulgaris. The company has license and collaboration agreements with Zai Lab (Shanghai) Co., Ltd. and Allergan plc; license agreement with Tufts University to develop and commercialize products for the treatment or prevention of bacterial or microbial diseases, or medical conditions; and contract with Biomedical Advanced Research and Development Authority to support the development of NUZYRA for the treatment of pulmonary anthrax. In addition, it has license agreement with Tetraphase Pharmaceuticals, Inc. to develop, import, and sell the XERAVATM product, which is used for the treatment of complicated intra-abdominal infections caused by bacteria. Paratek Pharmaceuticals, Inc. was founded in 1996 and is headquartered in Boston, Massachusetts.

General Outlook

When we look at how much money they make before expenses, they keep 0.850% as profit. This shows they're good at controlling costs and are financially stable. Their operating profit, which is money made from regular business activities, is -0.201%. This means they run their business efficiently. Lastly, after paying all their bills, they still have a profit of -0.299%. This tells us they're good at keeping money after all costs.

Return on Investments

The company's asset efficiency, represented by a robust -0.287% return, is a testament to Paratek Pharmaceuticals, Inc.'s adeptness in optimizing resource deployment. Paratek Pharmaceuticals, Inc.'s utilization of its assets to generate profits is strikingly evident through a noteworthy return on equity of 0.224%. Furthermore, the proficiency of Paratek Pharmaceuticals, Inc. in capital utilization is underscored by a remarkable 0.494% return on capital employed.

Stock Prices

Paratek Pharmaceuticals, Inc.'s stock prices have been subject to undulating patterns. The peak stock value during this interval surged to $2.23, while its low point bottomed out at $2.19. This variance in figures offers investors a lucid insight into the roller-coaster ride that is Paratek Pharmaceuticals, Inc.'s stock market.

Liquidity Ratios

Analyzing PRTK liquidity ratios reveals its financial health of the firm. The current ratio of 51.93% gauges short-term asset coverage for liabilities. The quick ratio (42.05%) assesses immediate liquidity, while the cash ratio (21.07%) indicates cash reserves.

cards.indicatorcards.value
Current Ratio51.93%
Quick Ratio42.05%
Cash Ratio21.07%

Profitability Ratios

PRTK profitability indicators offer a lens into its earnings landscape. A pretax profit margin of -29.80% underscores its earnings before tax deductions. The effective tax rate stands at -0.41%, revealing its tax efficiency. The net income per EBT, 100.41%, and the EBT per EBIT, 148.59%, provide insights into its earnings hierarchy. Lastly, with an EBIT per revenue ratio of -20.05%, we grasp its operational profitability.

cards.indicatorcards.value
Pretax Profit Margin-29.80%
Effective Tax Rate-0.41%
Net Income per EBT100.41%
EBT per EBIT148.59%
EBIT per Revenue-20.05%

Operational Efficiency

Operational metrics shed light on its business agility. With an operating cycle of 0.52, it details the span from stock purchase to revenue.

cards.indicatorcards.value
Days of Sales Outstanding42
Days of Inventory Outstanding199
Operating Cycle310.00
Days of Payables Outstanding51
Cash Conversion Cycle259
Receivables Turnover3.29
Payables Turnover7.09
Inventory Turnover1.83
Fixed Asset Turnover63.62
Asset Turnover0.96

Cash Flow Ratios

Peering into the cash flow metrics reveals liquidity and operational efficiency. The operating cash flow per share, -0.19, and free cash flow per share, -0.19, depict cash generation on a per-share basis. The cash per share value, 0.75, showcases liquidity position. Lastly, the operating cash flow sales ratio, -0.08, offers insight into cash flow relative to sales.

cards.indicatorcards.value
Operating Cash Flow per Share-0.19
Free Cash Flow per Share-0.19
Cash per Share0.75
Operating Cash Flow Sales Ratio-0.08
Free Cash Flow to Operating Cash Flow Ratio1.01
Cash Flow Coverage Ratio-0.04
Short Term Coverage Ratio-0.07
Capital Expenditure Coverage Ratio-158.81
Dividend Paid and Capex Coverage Ratio-158.81

Debt and Leverage Ratios

Diving into debt and leverage metrics unveils the company's financial structure. The debt ratio, at 178.17%, highlights its total liabilities relative to assets. With a debt-equity ratio of -1.29, we discern the balance between debt and equity financing. The long-term debt to capitalization, -90.59%, and total debt to capitalization, 444.86%, ratios shed light on its capital structure. An interest coverage of -1.96 indicates its ability to manage interest expenses.

cards.indicatorcards.value
Debt Ratio178.17%
Debt Equity Ratio-1.29
Long Term Debt to Capitalization-90.59%
Total Debt to Capitalization444.86%
Interest Coverage-1.96
Cash Flow to Debt Ratio-0.04
Company Equity Multiplier-0.72

Per Share Data

Speaking about the per share data offers a perceptive view of financial distribution. The revenue per share, 2.77, provides a glimpse into top-line earnings distributed across each share. Net income per share, -1.17, reflects the portion of profit attributed to each share. The book value per share, -3.14, represents the net asset value distributed per share, while the tangible book value per share, -3.16, excludes intangible assets.

cards.indicatorcards.value
Revenue Per Share2.77
Net Income Per Share-1.17
Book Value Per Share-3.14
Tangible Book Value Per Share-3.16
Shareholders Equity Per Share-3.14
Interest Debt Per Share5.08

Growth Ratios

Delving into growth metrics provides a snapshot of financial expansion. The revenue growth rate, 24.67%, indicates top-line expansion, while the gross profit growth, 28.48%, reveals profitability trends. EBIT growth, -12.35%, and operating income growth, -12.35%, offer insights into operational profitability progression. The net income growth, -7.59%, showcases bottom-line expansion, and the EPS growth, 4.10%, measures the growth in earnings per share.

cards.indicatorcards.value
Revenue Growth24.67%
Gross Profit Growth28.48%
EBIT Growth-12.35%
Operating Income Growth-12.35%
Net Income Growth-7.59%
EPS Growth4.10%
EPS Diluted Growth4.10%
Weighted Average Shares Growth12.34%
Weighted Average Shares Diluted Growth12.34%
Operating Cash Flow Growth-37.01%
Free Cash Flow Growth-36.04%
10-Year Revenue Growth per Share-64.27%
5-Year Revenue Growth per Share489.55%
3-Year Revenue Growth per Share449.53%
10-Year Operating CF Growth per Share88.63%
5-Year Operating CF Growth per Share58.48%
3-Year Operating CF Growth per Share70.25%
10-Year Net Income Growth per Share86.18%
5-Year Net Income Growth per Share64.80%
3-Year Net Income Growth per Share70.24%
10-Year Shareholders Equity Growth per Share-104.68%
5-Year Shareholders Equity Growth per Share-202.10%
3-Year Shareholders Equity Growth per Share-159.63%
Receivables Growth135.64%
Inventory Growth50.32%
Asset Growth-6.16%
Book Value per Share Growth-19.15%
Debt Growth1.05%
R&D Expense Growth24.61%

Other Metrics

Venturing into other key metrics unveils diverse facets of financial performance. The enterprise value, 325,871,335.6, captures the company's total value, considering both debt and equity. Income quality, 1.04, assesses the reliability of reported earnings. The ratio of intangibles to total assets, 0.48%, indicates the value of non-physical assets, and capex to operating cash flow, 0.05%, measures reinvestment capability.

cards.indicatorcards.value
Enterprise Value325,871,335.6
Income Quality1.04
Research and Development to Revenue25.08%
Intangibles to Total Assets0.48%
Capex to Operating Cash Flow0.05%
Capex to Revenue-0.02%
Capex to Depreciation-7.35%
Stock-Based Compensation to Revenue8.17%
Graham Number9.09
Return on Tangible Assets-37.02%
Graham Net Net-4.46
Working Capital99,454,000
Tangible Asset Value-171,871,000
Net Current Asset Value-206,738,000
Invested Capital-2
Average Receivables55,577,500
Average Payables5,351,000
Average Inventory13,792,500
Days Sales Outstanding189
Days Payables Outstanding84
Days of Inventory On Hand262
ROIC-52.94%
ROE0.37%

Valuation Ratios

Exploring the valuation ratios offers insights into perceived market value. The price to book value ratio, -0.63, and the price to book ratio, -0.63, reflect the market's valuation relative to the company's book value. The price to sales ratio, 0.91, provides a perspective on valuation in relation to sales. Ratios like price to free cash flows, -11.76, and price to operating cash flows, -11.83, gauge market valuation against cash flow metrics.

cards.indicatorcards.value
Price Book Value Ratio-0.63
Price to Book Ratio-0.63
Price to Sales Ratio0.91
Price Cash Flow Ratio-11.83
Price Earnings to Growth Ratio0.18
Enterprise Value Multiple3.28
Price Fair Value-0.63
Price to Operating Cash Flow Ratio-11.83
Price to Free Cash Flows Ratio-11.76
Price to Tangible Book Ratio-0.59
Enterprise Value to Sales2.16
Enterprise Value Over EBITDA-7.26
EV to Operating Cash Flow-4.93
Earnings Yield-62.50%
Free Cash Flow Yield-65.07%
security
Trusted project
“All information displayed on the site is verified. High quality project and financial performance”
Eugene Alexeev
NumFin Founder and investing enthusiast

Frequently Asked Question

How many company shares are outstanding in 2024?

There are stock number shares outstanding of Paratek Pharmaceuticals, Inc. (PRTK) on the NASDAQ in 2024.

What is P/E ratio of enterprise in 2024?

The current P/E ratio of enterprise is -3.052 in 2024.

What is the ticker symbol of Paratek Pharmaceuticals, Inc. stock?

The ticker symbol of Paratek Pharmaceuticals, Inc. stock is PRTK.

What is company IPO date?

IPO date of Paratek Pharmaceuticals, Inc. is 2009-02-03.

What is company current share price?

Current share price is 2.230 USD.

What is stock market cap today?

The market cap of stock today is 127828952.000.

What is PEG ratio in 2024?

The current 0.179 is 0.179 in 2024.

What is the number of employees in 2024?

In 2024 the company has 268.